» Articles » PMID: 37289729

Computational Simulations of Tumor Growth and Treatment Response: Benefits of High-frequency, Low-dose Drug Regimens and Concurrent Vascular Normalization

Overview
Specialty Biology
Date 2023 Jun 8
PMID 37289729
Authors
Affiliations
Soon will be listed here.
Abstract

Implementation of effective cancer treatment strategies requires consideration of how the spatiotemporal heterogeneities within the tumor microenvironment (TME) influence tumor progression and treatment response. Here, we developed a multi-scale three-dimensional mathematical model of the TME to simulate tumor growth and angiogenesis and then employed the model to evaluate an array of single and combination therapy approaches. Treatments included maximum tolerated dose or metronomic (i.e., frequent low doses) scheduling of anti-cancer drugs combined with anti-angiogenic therapy. The results show that metronomic therapy normalizes the tumor vasculature to improve drug delivery, modulates cancer metabolism, decreases interstitial fluid pressure and decreases cancer cell invasion. Further, we find that combining an anti-cancer drug with anti-angiogenic treatment enhances tumor killing and reduces drug accumulation in normal tissues. We also show that combined anti-angiogenic and anti-cancer drugs can decrease cancer invasiveness and normalize the cancer metabolic microenvironment leading to reduced hypoxia and hypoglycemia. Our model simulations suggest that vessel normalization combined with metronomic cytotoxic therapy has beneficial effects by enhancing tumor killing and limiting normal tissue toxicity.

Citing Articles

Mechanical forces in the tumor microenvironment: roles, pathways, and therapeutic approaches.

Zhang Y, Fu Q, Sun W, Yue Q, He P, Niu D J Transl Med. 2025; 23(1):313.

PMID: 40075523 PMC: 11899831. DOI: 10.1186/s12967-025-06306-8.


Using mathematical modelling and AI to improve delivery and efficacy of therapies in cancer.

Harkos C, Hadjigeorgiou A, Voutouri C, Kumar A, Stylianopoulos T, Jain R Nat Rev Cancer. 2025; .

PMID: 39972158 DOI: 10.1038/s41568-025-00796-w.


Transport Barriers Influence the Activation of Anti-Tumor Immunity: A Systems Biology Analysis.

Nikmaneshi M, Baish J, Zhou H, Padera T, Munn L Adv Sci (Weinh). 2023; 10(36):e2304076.

PMID: 37949675 PMC: 10754116. DOI: 10.1002/advs.202304076.

References
1.
Mpekris F, Voutouri C, Panagi M, Baish J, Jain R, Stylianopoulos T . Normalizing tumor microenvironment with nanomedicine and metronomic therapy to improve immunotherapy. J Control Release. 2022; 345:190-199. PMC: 9168447. DOI: 10.1016/j.jconrel.2022.03.008. View

2.
Seano G, Jain R . Vessel co-option in glioblastoma: emerging insights and opportunities. Angiogenesis. 2019; 23(1):9-16. PMC: 7012982. DOI: 10.1007/s10456-019-09691-z. View

3.
Yapp D, Wong M, Kyle A, Valdez S, Tso J, Yung A . The differential effects of metronomic gemcitabine and antiangiogenic treatment in patient-derived xenografts of pancreatic cancer: treatment effects on metabolism, vascular function, cell proliferation, and tumor growth. Angiogenesis. 2016; 19(2):229-44. PMC: 4819514. DOI: 10.1007/s10456-016-9503-z. View

4.
Stephanou A, Lesart A, Deverchere J, Juhem A, Popov A, Esteve F . How tumour-induced vascular changes alter angiogenesis: Insights from a computational model. J Theor Biol. 2017; 419:211-226. DOI: 10.1016/j.jtbi.2017.02.018. View

5.
Padera T, Kadambi A, Tomaso E, Carreira C, Brown E, Boucher Y . Lymphatic metastasis in the absence of functional intratumor lymphatics. Science. 2002; 296(5574):1883-6. DOI: 10.1126/science.1071420. View